Zobrazeno 1 - 10
of 936
pro vyhledávání: ''
Autor:
Hongying Pan, Xiangmin Tong, Shufang Xie, Chen Yang, Weimin Fan, Shibing Wang, Wen Lei, Yi Wu
Publikováno v:
Oncology Reports
Non‑Hodgkin lymphoma (NHL) is a form of lymphoid malignancy, with diffuse large B cell lymphoma (DLBCL) being the most common NHL isoform. Approximately half of patients with DLBCL are successfully cured via first‑line Rituximab, Cyclophosphamide
Autor:
Agnieszka Szczygieł, Joanna Rossowska, Katarzyna Węgierek‑Ciura, Jagoda Mierzejewska, Elżbieta Pajtasz‑Piasecka, Marta Świtalska, Tomasz M. Goszczyński, Natalia Anger‑Góra
Publikováno v:
Oncology Reports
Chemotherapy with low-molecular weight compounds, despite elimination of cancer cells, entails adverse effects. To overcome this disadvantage, innovative drug delivery systems are being developed, including conjugation of macromolecular carriers with
Autor:
Dongxia Wang, Peng Lin, Xing Li, Min Jia, Danying Li, Wen Qiu, Bingxuan Yang, Lili Xu, Bijia Su, Lijun Mo, Hongwei Li, Jinlong Li, Zhongxin Zhou, Jiaxu Ying
Publikováno v:
Oncology Reports
Bladder cancer is a common tumor type of the urinary system, which has high levels of morbidity and mortality. The first‑line treatment is cisplatin‑based combination chemotherapy, but a significant proportion of patients relapse due to the devel
Autor:
Marcella Mottolese, Alessandra Verdina, Isabella Sperduti, Giuliana Di Rocco, Carla Azzurra Amoreo, Simonetta Buglioni, Micol Di Segni, Silvia Soddu
Publikováno v:
Oncology Reports. 45:899-910
Colorectal cancer (CRC) is the third most frequently diagnosed type of cancer worldwide. Stage II CRC accounts for ~25% all CRC cases and their management after surgical resection remains a clinical dilemma due to the lack of reliable criteria for id
Publikováno v:
Oncology Reports
Studies have shown that suppression of both the JAK/STAT3 pathway and epithelial-mesenchymal transition (EMT) may overturn the resistance of non-small cell lung cancer (NSCLC) cells to gefitinib. Zoledronic acid (ZA) injection is used to treat and pr
Publikováno v:
Oncology Reports
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is widely used in the treatment of non‑small cell lung cancer (NSCLC). However, erlotinib resistance leads to high mortality in patients with NSCLC, while the ac
Autor:
Nikolaos Ioannou, Said Abdullah Khelwatty, Helmout Modjtahedi, Satvinder Mudan, Angus G. Dalgleish, Tanzeel Khan, Alan M. Seddon
Publikováno v:
Oncology Reports
Pancreatic cancer is one of the most aggressive, heterogeneous and fatal type of human cancers for which more effective therapeutic agents are urgently needed. Here, we investigated the sensitivity of a panel of seven human pancreatic cancer cell lin
Autor:
Cheng Chen, Hongjin Wu, Deshengyue Kong, Yu Xu, Zunyue Zhang, Fengrong Chen, Lei Zou, Ziwei Li, Jin Shui, Huayou Luo, Shi‑He Liu, Juehua Yu, Kunhua Wang, F. Brunicardi
Publikováno v:
Oncology Reports
Statins, a class of commonly prescribed cholesterol‑lowering medications, have been revealed to influence the risk of multiple types of cancer. However, the antitumor effects of statins on pancreatic cancer and their differential efficacy among a v
Autor:
Juichiro Yoshida, Yoshito Itoh, Kaname Oka, Katsura Mizushima, Naoyuki Sakamoto, Kazuhiro Kamada, Tomohisa Takagi, Yuji Naito, Yuki Endo, Ken Inoue, Takayuki Ota, Tetsuya Okayama, Kazuhiko Uchiyama, Takeshi Ishikawa, Shinya Matsumura, Yasuko Hirai
Publikováno v:
Oncology Reports. 44:371-381
Epithelial‑mesenchymal transition (EMT) is considered a crucial event in the development of cancer metastasis. Metformin is a drug used in the treatment of type 2 diabetes. Recently, increasing evidence has indicated that metformin possesses anti
Autor:
Hyung-Don Kim, Eunyoung Tak, Tae Won Kim, Young-Ra Cho, Jeong Eun Kim, Yong Sang Hong, Chloe Soohyun Jang, Jihun Kim, Minhee Kim, Sueun Choi, Buhm Han, Sun Young Kim
Publikováno v:
Oncology Reports
Neurofibromin 1 (NF1) is a tumor suppressor that has been previously reported to regulate RAS-MAPK signaling. The present study investigated the possible relationship between NF1 expression and anti-EGFR antibody (cetuximab) sensitivity in colorectal